Prevention of cytomegalovirus disease in transplant recipients
- 25 November 1995
- journal article
- Published by Elsevier in The Lancet
- Vol. 346 (8987) , 1380-1381
- https://doi.org/10.1016/s0140-6736(95)92401-9
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipientsThe Lancet, 1995
- Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant RecipientsAnnals of Internal Medicine, 1995
- A PROSPECTIVE RANDOMIZED TRIAL COMPARING SEQUENTIAL GANCICLOVIR-HIGH DOSE ACYCLOVIR TO HIGH DOSE ACYCLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN ADULT LIVER TRANSPLANT RECIPIENTSTransplantation, 1994
- Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantationThe Lancet, 1994
- Cytomegalovirus Immune Globulin Prophylaxis in Liver TransplantationAnnals of Internal Medicine, 1993
- Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients: Results of a Placebo-Controlled, Double-Blind TrialAnnals of Internal Medicine, 1993
- Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow TransplantAnnals of Internal Medicine, 1993
- Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1991
- Intravenous Immune Globulin for Prevention of Cytomegalovirus Infection and Interstitial Pneumonia After Bone Marrow TransplantationAnnals of Internal Medicine, 1987
- Cytomegalovirus Immune Globulin and Seronegative Blood Products to Prevent Primary Cytomegalovirus Infection after Marrow TransplantationNew England Journal of Medicine, 1986